Particular association of clinical and genetic features with autoimmunity to citrullinated α-enolase in rheumatoid arthritis

Arthritis and Rheumatism

Volumn 63, Issue 3, 2011, Pages 654-661

  Montes, Ariana ^a   Dieguez Gonzalez, Rebeca ^a   Perez Pampin, Eva ^a   Calaza, Manuel ^a   Mera Varela, Antonio ^a   Gomez Reino, Juan J ^a   Gonzalez, Antonio ^a  

^a UNIVERSITY OF SANTIAGO DE COMPOSTELA   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA ENOLASE; ANTIBODY; CITRULLINATED ALPHA ENOLASE PEPTIDE ANTIBODY; CITRULLINE; CYCLIC CITRULLINATED PEPTIDE ANTIBODY; DNA; EPITOPE; HLA DR ANTIGEN; RHEUMATOID FACTOR; UNCLASSIFIED DRUG;

ADULT; ALLELE; ARTHRITIS; ARTICLE; AUTOIMMUNITY; CLINICAL FEATURE; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; GENOTYPE; HEREDITY; HLA SYSTEM; HUMAN; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; RHEUMATOID ARTHRITIS; RISK ASSESSMENT; SERUM; SINGLE NUCLEOTIDE POLYMORPHISM;

AGED; ANTIBODY SPECIFICITY; ARTHRITIS, RHEUMATOID; AUTOANTIBODIES; DNA-BINDING PROTEINS; EPITOPES; FEMALE; GENETIC PREDISPOSITION TO DISEASE; GENOTYPE; HLA-DRB1 CHAINS; HUMANS; MALE; MIDDLE AGED; PEPTIDES, CYCLIC; PHOSPHOPYRUVATE HYDRATASE; POLYMORPHISM, SINGLE NUCLEOTIDE; PREVALENCE; PROTEIN TYROSINE PHOSPHATASE, NON-RECEPTOR TYPE 22; RISK FACTORS; SMOKING; TUMOR MARKERS, BIOLOGICAL; TUMOR SUPPRESSOR PROTEINS;

EID: 79953673569     PISSN: 00043591     EISSN: 15290131     Source Type: Journal    
DOI: 10.1002/art.30186     Document Type: Article

References (47)

1. Kroot EJ, de Jong BA, van Leeuwen MA, Swinkels H, van den Hoogen FH, van 't Hof M, et al. The prognostic value of anti-cyclic citrullinated peptide antibody in patients with recentonset rheumatoid arthritis. Arthritis Rheum 2000;43:1831-5.
2. Schellekens GA, Visser H, de Jong BA, van den Hoogen FH, Hazes JM, Breedveld FC, et al. The diagnostic properties of rheumatoid arthritis antibodies recognizing a cyclic citrullinated peptide. Arthritis Rheum 2000;43:155-63. (Pubitemid 30368225)
3. Aletaha D, Neogi T, Silman AJ, Funovits J, Felson DT, Bingham CO III, et al. 2010 rheumatoid arthritis classification criteria: an American College of Rheumatology/European League Against Rheumatism collaborative initiative. Arthritis Rheum 2010;62: 2569-81.
4. Klareskog L, Widhe M, Hermansson M, Ronnelid J. Antibodies to citrullinated proteins in arthritis: pathology and promise. Curr Opin Rheumatol 2008;20:300-5. (Pubitemid 351483320)
5. Van der Helm-van Mil AH, Verpoort KN, Breedveld FC, Toes RE, Huizinga TW. Antibodies to citrullinated proteins and differences in clinical progression of rheumatoid arthritis. Arthritis Res Ther 2005;7:R949-58.
6. Bukhari M, Thomson W, Naseem H, Bunn D, Silman A, Symmons D, et al. The performance of anti-cyclic citrullinated peptide antibodies in predicting the severity of radiologic damage in inflammatory polyarthritis: results from the Norfolk Arthritis Register. Arthritis Rheum 2007;56:2929-35. (Pubitemid 47502739)
7. Machold KP, Stamm TA, Nell VP, Pflugbeil S, Aletaha D, Steiner G, et al. Very recent onset rheumatoid arthritis: clinical and serological patient characteristics associated with radiographic progression over the first years of disease. Rheumatology (Oxford) 2007;46:342-9. (Pubitemid 46189798)
8. Sanmarti R, Gomez-Centeno A, Ercilla G, Larrosa M, Vinas O, Vazquez I, et al. Prognostic factors of radiographic progression in early rheumatoid arthritis: a two year prospective study after a structured therapeutic strategy using DMARDs and very low doses of glucocorticoids. Clin Rheumatol 2007;26:1111-8. (Pubitemid 46863954)
9. De Vries-Bouwstra JK, Goekoop-Ruiterman YP, Verpoort KN, Schreuder GM, Ewals JA, Terwiel JP, et al. Progression of joint damage in early rheumatoid arthritis: association with HLA-DRB1, rheumatoid factor, and anti-citrullinated protein antibodies in relation to different treatment strategies. Arthritis Rheum 2008;58:1293-8. (Pubitemid 351705918)
10. Farragher TM, Lunt M, Plant D, Bunn DK, Barton A, Symmons DP. Benefit of early treatment in inflammatory polyarthritis patients with anti-cyclic citrullinated peptide antibodies versus those without antibodies. Arthritis Care Res (Hoboken) 2010;62: 664-75.
11. Potter C, Hyrich KL, Tracey A, Lunt M, Plant D, Symmons DP, et al. Association of rheumatoid factor and anti-cyclic citrullinated peptide positivity, but not carriage of shared epitope or PTPN22 susceptibility variants, with anti-tumour necrosis factor response in rheumatoid arthritis. Ann Rheum Dis 2009;68:69-74.
12. Dorner T, Kinnman N, Tak PP. Targeting B cells in immunemediated inflammatory disease: a comprehensive review of mechanisms of action and identification of biomarkers. Pharmacol Ther 2010;125:464-75.
13. Van Gaalen FA, van Aken J, Huizinga TW, Schreuder GM, Breedveld FC, Zanelli E, et al. Association between HLA class II genes and autoantibodies to cyclic citrullinated peptides (CCPs) influences the severity of rheumatoid arthritis. Arthritis Rheum 2004;50:2113-21. (Pubitemid 38924388)
14. Irigoyen P, Lee AT, Wener MH, Li W, Kern M, Batliwalla F, et al. Regulation of anti-cyclic citrullinated peptide antibodies in rheumatoid arthritis: contrasting effects of HLA-DR3 and the shared epitope alleles. Arthritis Rheum 2005;52:3813-8. (Pubitemid 41798219)
15. Kokkonen H, Johansson M, Innala L, Jidell E, Rantapaa-Dahlqvist S. The PTPN22 1858C/T polymorphism is associated with anti-cyclic citrullinated peptide antibody-positive early rheumatoid arthritis in northern Sweden. Arthritis Res Ther 2007;9: R56.
16. Kurreeman FA, Padyukov L, Marques RB, Schrodi SJ, Seddighzadeh M, Stoeken-Rijsbergen G, et al. A candidate gene approach identifies the TRAF1/C5 region as a risk factor for rheumatoid arthritis. PLoS Med 2007;4:e278.
17. Dieguez-Gonzalez R, Calaza M, Perez-Pampin E, de la Serna AR, Fernandez-Gutierrez B, Castaneda S, et al. Association of interferon regulatory factor 5 haplotypes, similar to that found in systemic lupus erythematosus, in a large subgroup of patients with rheumatoid arthritis. Arthritis Rheum 2008;58:1264-74. (Pubitemid 351705915)
18. Orozco G, Alizadeh BZ, Delgado-Vega AM, Gonzalez-Gay MA, Balsa A, Pascual-Salcedo D, et al. Association of STAT4 with rheumatoid arthritis: a replication study in three European populations. Arthritis Rheum 2008;58:1974-80. (Pubitemid 351988089)
19. Klareskog L, Stolt P, Lundberg K, Kallberg H, Bengtsson C, Grunewald J, et al, for the Epidemiological Investigation of Rheumatoid Arthritis Study Group. A new model for an etiology of rheumatoid arthritis: smoking may trigger HLA-DR (shared epitope)-restricted immune reactions to autoantigens modified by citrullination. Arthritis Rheum 2006;54:38-46. (Pubitemid 43122184)
20. Linn-Rasker SP, van der Helm-van Mil AH, van Gaalen FA, Kloppenburg M, de Vries RR, le Cessie S, et al. Smoking is a risk factor for anti-CCP antibodies only in rheumatoid arthritis patients who carry HLA-DRB1 shared epitope alleles. Ann Rheum Dis 2006;65:366-71. (Pubitemid 43268227)
21. Pedersen M, Jacobsen S, Klarlund M, Pedersen BV, Wiik A, Wohlfahrt J, et al. Environmental risk factors differ between rheumatoid arthritis with and without auto-antibodies against cyclic citrullinated peptides. Arthritis Res Ther 2006;8:R133.
22. Lee HS, Irigoyen P, Kern M, Lee A, Batliwalla F, Khalili H, et al. Interaction between smoking, the shared epitope, and anti-cyclic citrullinated peptide: a mixed picture in three large North American rheumatoid arthritis cohorts. Arthritis Rheum 2007;56: 1745-53. (Pubitemid 47110374)
23. Bang SY, Lee KH, Cho SK, Lee HS, Lee KW, Bae SC. Smoking increases rheumatoid arthritis susceptibility in individuals carrying the HLA-DRB1 shared epitope, regardless of rheumatoid factor or anti-cyclic citrullinated peptide antibody status. Arthritis Rheum 2010;62:369-77.
24. Mikuls TR, Hughes LB, Westfall AO, Holers VM, Parrish L, van der Heijde D, et al. Cigarette smoking, disease severity and autoantibody expression in African Americans with recent-onset rheumatoid arthritis. Ann Rheum Dis 2008;67:1529-34.
25. Klareskog L, Ronnelid J, Lundberg K, Padyukov L, Alfredsson L. Immunity to citrullinated proteins in rheumatoid arthritis. Annu Rev Immunol 2008;26:651-75. (Pubitemid 351600388)
26. Mahdi H, Fisher BA, Kallberg H, Plant D, Malmstrom V, Ronnelid J, et al. Specific interaction between genotype, smoking and autoimmunity to citrullinated α-enolase in the etiology of rheumatoid arthritis. Nat Genet 2009;41:1319-24.
27. Kinloch A, Tatzer V, Wait R, Peston D, Lundberg K, Donatien P, et al. Identification of citrullinated a-enolase as a candidate autoantigen in rheumatoid arthritis. Arthritis Res Ther 2005;7: R1421-9.
28. Kinloch A, Lundberg K, Wait R, Wegner N, Lim NH, Zendman AJ, et al. Synovial fluid is a site of citrullination of autoantigens in inflammatory arthritis. Arthritis Rheum 2008;58:2287-95.
29. Lundberg K, Kinloch A, Fisher BA, Wegner N, Wait R, Charles P, et al. Antibodies to citrullinated a-enolase peptide 1 are specific for rheumatoid arthritis and cross-react with bacterial enolase. Arthritis Rheum 2008;58:3009-19.
30. Snir O, Widhe M, von Spee C, Lindberg J, Padyukov L, Lundberg K, et al. Multiple antibody reactivities to citrullinated antigens in sera from patients with rheumatoid arthritis: association with HLA-DRB1 alleles. Ann Rheum Dis 2009;68:736-43.
31. Satpute SR, Durai M, Moudgil KD. Antigen-specific tolerogenic and immunomodulatory strategies for the treatment of autoimmune arthritis. Semin Arthritis Rheum 2008;38:195-207.
32. Arnett FC, Edworthy SM, Bloch DA, McShane DJ, Fries JF, Cooper NS, et al. The American Rheumatism Association 1987 revised criteria for the classification of rheumatoid arthritis. Arthritis Rheum 1988;31:315-24. (Pubitemid 18091653)
33. Hosmer DW, Lemeshow S. Confidence interval estimation of interaction. Epidemiology 1992;3:452-6.
34. Van der Helm-van Mil AH, Verpoort KN, le Cessie S, Huizinga TW, de Vries RR, Toes RE. The HLA-DRB1 shared epitope alleles differ in the interaction with smoking and predisposition to antibodies to cyclic citrullinated peptide. Arthritis Rheum 2007; 56:425-32.
35. Fernandez E, Schiaffino A, Garcia M, Salto E, Villalbi JR, Borras JM. Smoking in Spain, 1945-1995: a retrospective analysis based on the Spanish National Health Interview Surveys. Med Clin (Barc) 2003;120:14-6. In Spanish. (Pubitemid 36176056)
36. Perez-Rios M, Santiago-Perez MI, Carames SC, Alonso de la Iglesia B, Pintos AM, Vidal XH. Mortality associated to tobacco consumption in Galicia, Spain, 2001-2006. Rev Esp Salud Publica 2009;83:557-65. In Spanish.
37. Hernandez-Garcia I, Saenz-Gonzalez MC, Gonzalez-Celador R. Mortality attributable to smoking in Spain in 2006. An Sist Sanit Navar 2010;33:23-33. In Spanish.
38. Balsa A, Minaur NJ, Pascual-Salcedo D, McCabe C, Balas A, Fiddament B, et al. Class II MHC antigens in early rheumatoid arthritis in Bath (UK) and Madrid (Spain). Rheumatology (Oxford) 2000;39:844-9. (Pubitemid 30649510)
39. Pascual M, Nieto A, Lopez-Nevot MA, Ramal L, Mataran L, Caballero A, et al. Rheumatoid arthritis in southern Spain: toward elucidation of a unifying role of the HLA class II region in disease predisposition. Arthritis Rheum 2001;44:307-14. (Pubitemid 32207023)
40. Gregersen PK, Lee HS, Batliwalla F, Begovich AB. PTPN22: setting thresholds for autoimmunity. Semin Immunol 2006;18: 214-23. (Pubitemid 43903284)
41. Kallberg H, Padyukov L, Plenge RM, Ronnelid J, Gregersen PK, van der Helm-van Mil AH, et al. Gene-gene and gene-environment interactions involving HLA-DRB1, PTPN22, and smoking in two subsets of rheumatoid arthritis. Am J Hum Genet 2007;80: 867-75. (Pubitemid 46668455)
42. Bongartz T, Cantaert T, Atkins SR, Harle P, Myers JL, Turesson C, et al. Citrullination in extra-articular manifestations of rheumatoid arthritis. Rheumatology (Oxford) 2007;46:70-5. (Pubitemid 44932787)
43. Makrygiannakis D, af Klint E, Lundberg IE, Lofberg R, Ulfgren AK, Klareskog L, et al. Citrullination is an inflammationdependent process. Ann Rheum Dis 2006;65:1219-22.
44. Foulquier C, Sebbag M, Clavel C, Chapuy-Regaud S, Al Badine R, Mechin MC, et al. Peptidyl arginine deiminase type 2 (PAD-2) and PAD-4 but not PAD-1, PAD-3, and PAD-6 are expressed in rheumatoid arthritis synovium in close association with tissue inflammation. Arthritis Rheum 2007;56:3541-53. (Pubitemid 350100687)
45. Liao F, Li Z, Wang Y, Shi B, Gong Z, Cheng X. Porphyromonas gingivalis may play an important role in the pathogenesis of periodontitis-associated rheumatoid arthritis. Med Hypotheses 2009;72:732-5.
46. Hitchon CA, Chandad F, Ferucci ED, Willemze A, Ioan-Facsinay A, van der Woude D, et al. Antibodies to porphyromonas gingi-valis are associated with anticitrullinated protein antibodies in patients with rheumatoid arthritis and their relatives. J Rheumatol 2010;37:1105-12.
47. Verpoort KN, Cheung K, Ioan-Facsinay A, van der Helm-van Mil AH, de Vries-Bouwstra JK, Allaart CF, et al. Fine specificity of the anti-citrullinated protein antibody response is influenced by the shared epitope alleles. Arthritis Rheum 2007;56:3949-52. (Pubitemid 350262321)